Global Interleukin 17A Market Size By Type (ABY-035, CNTO-6785), By Application (Chronic Pain, Liver Cancer), By Region, And Segment Forecasts, 2023 to 2032

The Global Interleukin 17A Market was valued at USD 1.9 billion in 2023 and is projected to reach USD 4.5 billion by 2031, growing at a CAGR of 11.4% during the forecast period from 2023 to 2031. Interleukin 17A (IL-17A) is a pro-inflammatory cytokine primarily associated with autoimmune and inflammatory diseases. With the rising prevalence of conditions like psoriasis, ankylosing spondylitis, and rheumatoid arthritis, the demand for IL-17A targeted biologics is surging. The market is benefiting from continuous advancements in immunology research and the approval of novel monoclonal antibodies targeting IL-17A pathways.

Drivers:

1. Rising Prevalence of Autoimmune Disorders:

The increasing incidence of chronic autoimmune diseases globally is significantly driving demand for IL-17A inhibitors. Disorders such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis are on the rise, bolstering therapeutic adoption.

2. Advancements in Biologic Drug Development:

Innovations in monoclonal antibody engineering and the expansion of biologic therapies are enhancing treatment efficacy and targeting specificity, thus driving market growth.

3. Regulatory Approvals and Expanded Indications:

Recent FDA and EMA approvals for IL-17A inhibitors like secukinumab and ixekizumab across multiple indications are accelerating their uptake across various clinical applications.

Restraints:

1. High Treatment Costs:

The cost of biologic therapies targeting IL-17A remains high, limiting access in low- and middle-income regions. This cost barrier hampers broader adoption despite proven efficacy.

2. Risk of Adverse Effects and Immunogenicity:

As with many immunomodulators, IL-17A inhibitors carry risks of infections and immunogenic responses, which may reduce patient compliance and necessitate ongoing safety monitoring.

Opportunity:

1. Expansion into Emerging Markets:

With improving healthcare infrastructure and regulatory environments, emerging markets in Asia-Pacific and Latin America present substantial growth potential for IL-17A-based therapies.

2. Pipeline Advancements and Novel Biologics:

Multiple IL-17A-targeting agents are in late-stage clinical development, some with dual inhibition profiles (e.g., IL-17A/F inhibitors), offering improved outcomes and fueling market expansion.

3. Strategic Collaborations and Licensing:

Biopharmaceutical companies are increasingly engaging in co-development agreements and licensing deals to broaden their IL-17A drug portfolios and enhance global distribution networks.

Market by System Type Insights:

Based on system type, the Monoclonal Antibodies segment dominated the market in 2023. Drugs like Secukinumab and Ixekizumab are widely used in treating moderate to severe plaque psoriasis and other autoimmune diseases. The segment is expected to continue its dominance due to strong clinical evidence supporting their efficacy and safety.

Emerging system types include bispecific antibodies and fusion proteins, which are under clinical evaluation for multi-targeted therapeutic effects and reduced resistance.

Market by End-use Insights:

In terms of end-use, the Hospitals & Specialty Clinics segment accounted for the largest market share in 2023. These institutions are primary centers for biologic therapy administration and ongoing disease management for autoimmune patients.

The Homecare Settings segment is projected to grow rapidly as subcutaneous formulations and self-injection devices become more user-friendly and widely adopted, improving patient convenience and adherence.

Market by Regional Insights:

Geographically, North America led the global interleukin 17A market in 2023 due to high diagnosis rates, well-established healthcare systems, and the early adoption of biologics. The United States remains a major contributor, supported by favorable insurance coverage and strong presence of key pharmaceutical players.

Asia-Pacific is forecasted to register the fastest CAGR during the forecast period, driven by increasing healthcare access, rising awareness of autoimmune diseases, and greater adoption of targeted therapies.

Competitive Scenario:

Prominent players in the Global Interleukin 17A Market include:

Novartis AG

Eli Lilly and Company

AbbVie Inc.

Johnson & Johnson (Janssen Biotech)

Amgen Inc.

UCB S.A.

Sun Pharmaceutical Industries Ltd.

Innovent Biologics

Samsung Bioepis

Biogen Inc.

Key strategies among these players include R&D investments, geographic expansion, regulatory filings for new indications, and strategic collaborations.

Scope of Work – Global Interleukin 17A Market

Report Metric Details

Market Size (2023) USD 1.9 Billion

Projected Market Size (2031) USD 4.5 Billion

CAGR (2023-2031) 11.4%

Market Segments By System Type (Monoclonal Antibodies, Others); By End-use (Hospitals & Clinics, Homecare)

Growth Drivers Rise in autoimmune diseases, biologic advancements, regulatory approvals

Opportunities Emerging market expansion, novel biologics pipeline, self-administration devices

Key Market Developments:

2023: Novartis received additional indication approval for Cosentyx (secukinumab) for non-radiographic axial spondyloarthritis in major global markets.

2023: Eli Lilly's Taltz (ixekizumab) showed positive outcomes in a Phase 3 trial for pediatric plaque psoriasis, expanding its patient base.

2024: AbbVie announced collaboration with a biotech firm to develop a next-generation IL-17A/IL-17F dual inhibitor.

2024: Innovent Biologics launched a biosimilar version of an IL-17A monoclonal antibody in the China market, targeting affordable biologic access.

FAQs:

1) What is the current market size of the Global Interleukin 17A Market?

The market was valued at USD 1.9 billion in 2023.

2) What is the major growth driver of the Global Interleukin 17A Market?

Rising prevalence of autoimmune disorders and advancements in biologic drug development are key growth drivers.

3) Which is the largest region during the forecast period in the Global Interleukin 17A Market?

North America holds the largest market share due to advanced healthcare infrastructure and high treatment uptake.

4) Which segment accounted for the largest market share in Global Interleukin 17A Market?

The Monoclonal Antibodies segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Interleukin 17A Market?

Key players include Novartis AG, Eli Lilly and Company, AbbVie Inc., Amgen Inc., and UCB S.A.

Let me know if you’d like the same for a related immunology market or a custom infographic summarizing this report.